The Latest Breaking News from Big Pharma

Artificial intelligence can shave years off the development process, and companies like Japan’s Takeda are making large investments.

Some doctors, psychologists and eating disorder experts worry these new medications, originally developed to treat diabetes, could become a problem long-term.

Forget COVID-19, monkeypox and other viruses for the moment and consider another threat troubling infectious disease specialists: common urinary tract infections, or UTIs, that lead to emergency room visits and even hospitalizations because of the failure of oral antibiotics.

China’s muscling into the pharmaceutical industry, helping Big Pharma bite back against generics. But its global ambitions might turn the industry upside down.

Zelira Therapeutics (OTC: ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is about to begin a first-ever clinical trial of its own proprietary pain formula for the treatment of diabetic nerve pain against an as-y

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach for a full day of networking and education.

Terran Biosciences is slowly but surely finding its place in the psychedelics industry.

In “Sickening,” Harvard professor John Abramson chronicles the deceptive marketing practices of the drug industry

Waiving Covid vaccine patents would help poor countries fight the disease. Pharma giants won't let that happen